CCL2 and head and neck cancer: In this study, we analyzed the immune regulatory properties of EGFR signaling in head and neck cancer cells and showed that it suppresses type 1 cytokine-induced expression of CCL2, CCL5, CXCL9, CXCL10 and IL-6 while promoting the expression of IL-1β.